Prospective study of cigarette smoking and amyotrophic lateral sclerosis

American Journal of Epidemiology

Volumn 160, Issue 1, 2004, Pages 26-33

  Weisskopf, Marc G ^a   McCullough, M L ^b   Calle, E E ^b   Thun, M J ^b   Cudkowicz, M ^c   Ascherio, A ^a,d  

^a HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^b AMERICAN CANCER SOCIETY   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

^d BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Amyotrophic lateral sclerosis; Mortality; Motor neuron disease; Prospective studies

Indexed keywords

MORTALITY; RISK FACTOR; SMOKING;

ADULT; AMYOTROPHIC LATERAL SCLEROSIS; ARTICLE; CAUSE OF DEATH; CIGARETTE SMOKING; CONTROLLED STUDY; DEATH CERTIFICATE; FEMALE; HUMAN; INCIDENCE; LIFESTYLE; MALE; MORTALITY; PROSPECTIVE STUDY; RISK FACTOR;

ADULT; AMYOTROPHIC LATERAL SCLEROSIS; DEATH CERTIFICATES; EPIDEMIOLOGIC METHODS; FEMALE; HUMANS; INCIDENCE; INTERNATIONAL CLASSIFICATION OF DISEASES; LIFE STYLE; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; QUESTIONNAIRES; RISK; SEX DISTRIBUTION; SMOKING; UNITED STATES;

EID: 3042760758     PISSN: 00029262     EISSN: None     Source Type: Journal    
DOI: 10.1093/aje/kwh179     Document Type: Article

References (42)

1. Walling AD. Amyotrophic lateral sclerosis: Lou Gehrig's disease. Am Fam Physician 1999;59:1489-96.
2. del Aguila MA, Longstreth WT Jr, McGuire V, et al. Prognosis in amyotrophic lateral sclerosis: a population-based study. Neurology 2003;60:813-19.
3. Magnus T, Beck M, Giess R, et al. Disease progression in amyotrophic lateral sclerosis: predictors of survival. Muscle Nerve 2002;25:709-14.
4. Sorenson EJ, Stalker AP, Kurland LT, et al. Amyotrophic lateral sclerosis in Olmsted County, Minnesota, 1925 to 1998. Neurology 2002;59:280-2.
5. Drory VE, Birnbaum M, Korczyn AD, et al. Association of APOEε4 allele with survival in amyotrophic lateral sclerosis. J Neurol Sci 2001;190:17-20.
6. Louwerse ES, Visser CE, Bossuyt PM, et al. Amyotrophic lateral sclerosis: mortality risk during the course of the disease and prognostic factors. The Netherlands ALS Consortium. J Neurol Sci 1997;152(suppl 1):S10-17.
7. Siddique T, Nijhawan D, Hentati A. Familial amyotrophic lateral sclerosis. J Neural Transm Suppl 1997;49:219-33.
8. Armon C. Motor neuron disease. In: Gorelick PB, Alter M, eds. Handbook of neuroepidemiology. New York, NY: Dekker, 1994:407-56.
9. Armon C. Environmental risk factors for amyotrophic lateral sclerosis. Neuroepidemiology 2001;20:2-6.
10. Nelson LM. Epidemiology of ALS. Clin Neurosci 1996;3:327-31.
11. Chiba M, Masironi R. Toxic and trace elements in tobacco and tobacco smoke. Bull World Health Organ 1992;70:269-75.
12. Church DF, Pryor WA. Free-radical chemistry of cigarette smoke and its toxicological implications. Environ Health Perspect 1985;64:111-26.
13. 2-isoprostanes) in smokers-smoking as a cause of oxidative damage. N Engl J Med 1995; 332:1198-203.
14. Kamel F, Umbach DM, Munsat TL, et al. Association of cigarette smoking with amyotrophic lateral sclerosis. Neuroepidemiology 1999;18:194-202.
15. Nelson LM, McGuire V, Longstreth WT Jr, et al. Population-based case-control study of amyotrophic lateral sclerosis in western Washington State. I. Cigarette smoking and alcohol consumption. Am J Epidemiol 2000;151:156-63.
16. Pierce-Ruhland R, Patten BM. Repeat study of antecedent events in motor neuron disease. Ann Clin Res 1981;13:102-7.
17. Provinciali L, Giovagnoli AR. Antecedent events in amyotrophic lateral sclerosis: do they influence clinical onset and progression? Neuroepidemiology 1990;9:255-62.
18. Mitchell JD, Davies RB, al-Hamad A, et al. MND risk factors: an epidemiological study in the north west of England. J Neurol Sci 1995;129(suppl):61-4.
19. Granieri E, Carreras M, Tola R, et al. Motor neuron disease in the province of Ferrara, Italy, in 1964-1982. Neurology 1988; 38:1604-8.
20. Kondo K, Tsubaki T. Case-control studies of motor neuron disease: association with mechanical injuries. Arch Neurol 1981; 38:220-6.
21. Savettieri G, Salemi G, Arcara A, et al. A case-control study of amyotrophic lateral sclerosis. Neuroepidemiology 1991;10: 242-5.
22. Thun MJ, Calle EE, Rodriguez C, et al. Epidemiological research at the American Cancer Society. Cancer Epidemiol Biomarkers Prev 2000;9:861-8.
23. Calle EE, Terrell DD. Utility of the National Death Index for ascertainment of mortality among Cancer Prevention Study II participants. Am J Epidemiol 1993;137:235-41.
24. World Health Organization. International classification of diseases for oncology. 2nd ed. Geneva, Switzerland: World Health Organization, 1990.
25. Breslow NE, Day NE. Statistical methods in cancer research. Vol II. The design and analysis of cohort studies. Lyon, France: International Agency for Research on Cancer, 1987. (IARC scientific publication no. 82).
26. Li TM, Alberman E, Swash M. Clinical features and associations of 560 cases of motor neuron disease. J Neurol Neurosurg Psychiatry 1990;53:1043-5.
27. Buckley J, Warlow C, Smith P, et al. Motor neuron disease in England and Wales, 1959-1979. J Neurol Neurosurg Psychiatry 1983;46:197-205.
28. Chio A, Magnani C, Oddenino E, et al. Accuracy of death certificate diagnosis of amyotrophic lateral sclerosis. J Epidemiol Community Health 1992;46:517-18.
29. Hoffman PM, Brody JA. The reliability of death certificate reporting for amyotrophic lateral sclerosis. J Chronic Dis 1971; 24:5-8.
30. O'Malley F, Dean G, Elian M. Multiple sclerosis and motor neurone disease: survival and how certified after death. J Epidemiol Community Health 1987;41:14-17.
31. Bharucha NE, Schoenberg BS, Raven RH, et al. Geographic distribution of motor neuron disease and correlation with possible etiologic factors. Neurology 1983;33:911-15.
32. Lilienfeld DE, Chan E, Ehland J, et al. Rising mortality from motoneuron disease in the USA, 1962-84. Lancet 1989;1:710-13.
33. Riggs JE. Longitudinal Gompertzian analysis of amyotrophic lateral sclerosis mortality in the U.S., 1977-1986: evidence for an inherently susceptible population subset. Mech Ageing Dev 1990;55:207-20.
34. McGuire V, Longstreth WT Jr, Koepsell TD, et al. Incidence of amyotrophic lateral sclerosis in three counties in western Washington State. Neurology 1996;47:571-3.
35. Watkins ML, Erickson JD, Thun MJ, et al. Multivitamin use and mortality in a large prospective study. Am J Epidemiol 2000;152:149-62.
36. Hu H, Payton M, Korrick S, et al. Determinants of bone and blood lead levels among community-exposed middle-aged to elderly men. The Normative Aging Study. Am J Epidemiol 1996;144:749-59.
37. Mussalo-Rauhamaa H, Leppanen A, Salmela SS, et al. Cigarettes as a source of some trace and heavy metals and pesticides in man. Arch Environ Health 1986;41:49-55.
38. Mitchell JD. Amyotrophic lateral sclerosis: toxins and environment. Amyotroph Lateral Scler Other Motor Neuron Disord 2000;1:235-50.
39. McGuire V, Longstreth WT Jr, Nelson LM, et al. Occupational exposures and amyotrophic lateral sclerosis. A population-based case-control study. Am J Epidemiol 1997;145:1076-88.
40. Djordjevic MV, Fan J, Hoffmann D. Assessment of chlorinated pesticide residues in cigarette tobacco based on supercritical fluid extraction and GC-ECD. Carcinogenesis 1995;16:2627-32.
41. Michaud SE, Menard C, Guy LG, et al. Inhibition of hypoxia-induced angiogenesis by cigarette smoke exposure: impairment of the HIF-1α/VEGF pathway. FASEB J 2003;17:1150-2.
42. Lambrechts D, Storkebaum E, Morimoto M, et al. VEGF is a modifier of amyotrophic lateral sclerosis in mice and humans and protects motoneurons against ischemic death. Nat Genet 2003;34:383-94.